Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved..
In November 2021, Omicron BA.1, containing a raft of new spike mutations, emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection then led to a rapid succession of Omicron sub-lineages with waves of BA.2 and then BA.4/5 infection. Recently, many variants have emerged such as BQ.1 and XBB, which carry up to 8 additional receptor-binding domain (RBD) amino acid substitutions compared with BA.2. We describe a panel of 25 potent monoclonal antibodies (mAbs) generated from vaccinees suffering BA.2 breakthrough infections. Epitope mapping shows potent mAb binding shifting to 3 clusters, 2 corresponding to early-pandemic binding hotspots. The RBD mutations in recent variants map close to these binding sites and knock out or severely knock down neutralization activity of all but 1 potent mAb. This recent mAb escape corresponds with large falls in neutralization titer of vaccine or BA.1, BA.2, or BA.4/5 immune serum.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell reports - 42(2023), 4 vom: 25. Apr., Seite 112271 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dijokaite-Guraliuc, Aiste [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 04.10.2023 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.celrep.2023.112271 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355008637 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355008637 | ||
| 003 | DE-627 | ||
| 005 | 20240313233359.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.celrep.2023.112271 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM355008637 | ||
| 035 | |a (NLM)36995936 | ||
| 035 | |a (PII)S2211-1247(23)00282-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dijokaite-Guraliuc, Aiste |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.10.2023 | ||
| 500 | |a Date Revised 13.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a In November 2021, Omicron BA.1, containing a raft of new spike mutations, emerged and quickly spread globally. Intense selection pressure to escape the antibody response produced by vaccines or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection then led to a rapid succession of Omicron sub-lineages with waves of BA.2 and then BA.4/5 infection. Recently, many variants have emerged such as BQ.1 and XBB, which carry up to 8 additional receptor-binding domain (RBD) amino acid substitutions compared with BA.2. We describe a panel of 25 potent monoclonal antibodies (mAbs) generated from vaccinees suffering BA.2 breakthrough infections. Epitope mapping shows potent mAb binding shifting to 3 clusters, 2 corresponding to early-pandemic binding hotspots. The RBD mutations in recent variants map close to these binding sites and knock out or severely knock down neutralization activity of all but 1 potent mAb. This recent mAb escape corresponds with large falls in neutralization titer of vaccine or BA.1, BA.2, or BA.4/5 immune serum | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CP: Immunology | |
| 650 | 4 | |a CP: Microbiology | |
| 650 | 4 | |a SARS-CoV-2, BA.2, variant, mutation, RBD, antibodies, binding site, breakthrough, neutralizing, structure, COVID-19 | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 700 | 1 | |a Das, Raksha |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Daming |e verfasserin |4 aut | |
| 700 | 1 | |a Ginn, Helen M |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chang |e verfasserin |4 aut | |
| 700 | 1 | |a Duyvesteyn, Helen M E |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Jiandong |e verfasserin |4 aut | |
| 700 | 1 | |a Nutalai, Rungtiwa |e verfasserin |4 aut | |
| 700 | 1 | |a Supasa, Piyada |e verfasserin |4 aut | |
| 700 | 1 | |a Selvaraj, Muneeswaran |e verfasserin |4 aut | |
| 700 | 1 | |a de Silva, Thushan I |e verfasserin |4 aut | |
| 700 | 1 | |a Plowright, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Newman, Thomas A H |e verfasserin |4 aut | |
| 700 | 1 | |a Hornsby, Hailey |e verfasserin |4 aut | |
| 700 | 1 | |a Mentzer, Alexander J |e verfasserin |4 aut | |
| 700 | 1 | |a Skelly, Donal |e verfasserin |4 aut | |
| 700 | 1 | |a Ritter, Thomas G |e verfasserin |4 aut | |
| 700 | 1 | |a Temperton, Nigel |e verfasserin |4 aut | |
| 700 | 1 | |a Klenerman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Barnes, Eleanor |e verfasserin |4 aut | |
| 700 | 1 | |a Dunachie, Susanna J |e verfasserin |4 aut | |
| 700 | 0 | |a OPTIC consortium |e verfasserin |4 aut | |
| 700 | 1 | |a Roemer, Cornelius |e verfasserin |4 aut | |
| 700 | 1 | |a Peacock, Thomas P |e verfasserin |4 aut | |
| 700 | 1 | |a Paterson, Neil G |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a Hall, David R |e verfasserin |4 aut | |
| 700 | 1 | |a Fry, Elizabeth E |e verfasserin |4 aut | |
| 700 | 1 | |a Mongkolsapaya, Juthathip |e verfasserin |4 aut | |
| 700 | 1 | |a Ren, Jingshan |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, David I |e verfasserin |4 aut | |
| 700 | 1 | |a Screaton, Gavin R |e verfasserin |4 aut | |
| 700 | 1 | |a Conlon, Christopher |e investigator |4 oth | |
| 700 | 1 | |a Deeks, Alexandra |e investigator |4 oth | |
| 700 | 1 | |a Frater, John |e investigator |4 oth | |
| 700 | 1 | |a Gardiner, Siobhan |e investigator |4 oth | |
| 700 | 1 | |a Jämsén, Anni |e investigator |4 oth | |
| 700 | 1 | |a Jeffery, Katie |e investigator |4 oth | |
| 700 | 1 | |a Malone, Tom |e investigator |4 oth | |
| 700 | 1 | |a Phillips, Eloise |e investigator |4 oth | |
| 700 | 1 | |a Kronsteiner-Dobramysl, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Abraham, Priyanka |e investigator |4 oth | |
| 700 | 1 | |a Bibi, Sagida |e investigator |4 oth | |
| 700 | 1 | |a Lambe, Teresa |e investigator |4 oth | |
| 700 | 1 | |a Longet, Stephanie |e investigator |4 oth | |
| 700 | 1 | |a Tipton, Tom |e investigator |4 oth | |
| 700 | 1 | |a Carrol, Miles |e investigator |4 oth | |
| 700 | 1 | |a Stafford, Lizzie |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Cell reports |d 2012 |g 42(2023), 4 vom: 25. Apr., Seite 112271 |w (DE-627)NLM217067492 |x 2211-1247 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:4 |g day:25 |g month:04 |g pages:112271 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.celrep.2023.112271 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 4 |b 25 |c 04 |h 112271 | ||